• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pharma

Altimmune: GLP-1/Glucagon Receptor Agonist Pemvidutide Preserves Lean Mass During Weight Loss

byAdrian CheandFlaviu Trifoi
August 7, 2024
in Pharma
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter
  1. Patients on pemvidutide experienced only 21.9% of weight loss attributable to lean mass.
  2. Pemvidutide preserves muscle tissue and prioritizes fat loss better than current incretin weight loss drugs.

The Latest

Phase 2 of the MOMENTUM clinical trial tested pemvidutide in patients with obesity over 48 weeks. The trial enrolled 391 participants who were obese or overweight with at least one co-morbidity but without diabetes. The study participants were randomized equally into 4 groups and given 1.2 mg, 1.8mg, or 2.4 mg of pemvidutide or placebo weekly in conjunction with diet and exercise. At week 48, participants who received pemvidutide achieved a mean weight loss of 10.3%, 11.2%, 15.6%, and 2.2% at the 1.2 mg, 1.8 mg, and 2.4 mg doses and placebo, respectively. Additionally, a subgroup of 50 participants was evaluated for body composition analysis. The results showed that those treated with pemvidutide had an average weight loss of 21.9% attributable to lean mass and 78.1% of weight loss attributable to fat.

Physician’s Perspective

There are over 1 billion people worldwide with obesity which has shown to carry an economic burden of $705 billion in the United States alone. Obesity is linked with conditions such as hypertension, cardiovascular disease, diabetes, dyslipidemia, and metabolic dysfunction-associated steatotic liver disease. With the tremendous burden of obesity, there is a need for treatment options that address obesity and its associated comorbidities. The pemvidutide trial demonstrated not only significant weight loss in patients but also unprecedented preservation of lean mass. Other similar incretin weight loss drugs have publicly reported a loss of as much as 40% of lean mass compared to only 21.9% for pemvidutide. Muscle tissue preservation is important in maintaining weight loss and enhancing physical function. As a result, this unique property of pemvidutide differentiates it from other available treatments for obesity.

Molecular Targets

Pemvidutide is a novel, peptide-based GLP-1/glucagon dual receptor agonist developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. Normally, GLP-1 and glucagon work in the body to suppress appetite and increase energy expenditure, respectively. Glucagon also has direct effects on hepatic fat metabolism which can rapidly reduce levels of liver fat and serum lipids. Pemvidutide works by activating the GLP-1 and glucagon receptors, thus artificially enhancing the effects of these molecules in the body.

RELATED REPORTS

Body mass index-specific waist circumference thresholds may improve mortality risk stratification in women

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

Semaglutide may improve cardiovascular outcomes versus empagliflozin in patients with diabetes

Company History

Altimmune is a biopharmaceutical company in Gaithersburg, Maryland focused on developing innovative peptide-based therapeutics. Pemvidutide is the company’s first developed drug which has already been granted fast-track designation by the U.S. FDA for the treatment of metabolic dysfunction-associated steatotic liver disease.

 

Further Reading: https://ir.altimmune.com/news-releases/news-release-details/altimmune-presents-data-phase-2-momentum-trial-pemvidutide

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: altimmuneglp1glucagonlean massobesitypemvidutideweight loss
Previous Post

#VisualAbstract: Twice-Yearly Lenacapavir Prevented HIV Infections in Cisgender Young Girls and Adolescent Women

Next Post

#VisualAbstract: Surgical Navigation Improves Outcomes for Targeted Retroperitoneal Lymph Node Removal

RelatedReports

Majority of obese tenth-graders already obese by fifth grade
Chronic Disease

Body mass index-specific waist circumference thresholds may improve mortality risk stratification in women

July 7, 2025
Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

June 23, 2025
Compliance-linked incentives increase infant immunizations rates in rural India
Endocrinology

Semaglutide may improve cardiovascular outcomes versus empagliflozin in patients with diabetes

June 16, 2025
#VisualAbstract: Once-Weekly Mazdutide Reduced Body Weight in Obese or Overweight Chinese Adults
StudyGraphics

#VisualAbstract: Once-Weekly Mazdutide Reduced Body Weight in Obese or Overweight Chinese Adults

June 16, 2025
Next Post
#VisualAbstract: Surgical Navigation Improves Outcomes for Targeted Retroperitoneal Lymph Node Removal

#VisualAbstract: Surgical Navigation Improves Outcomes for Targeted Retroperitoneal Lymph Node Removal

#VisualAbstract Tetravalent Protein COVID-19 Vaccine SCTV01E Reduces Risk of COVID-19 Infectious for up to 98 Days

#VisualAbstract Tetravalent Protein COVID-19 Vaccine SCTV01E Reduces Risk of COVID-19 Infectious for up to 98 Days

Stroke expansion following intra-arterial therapy may explain worse outcomes

Long-term colchicine does not reduce recurrent events following ischemic stroke

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.